



Corrigendum

Corrigendum to “Development of dextrin-amphotericin B formulations for the treatment of Leishmaniasis” [Int. J. Biol. Macromol., 15 (2020) 276–288]



R. Silva-Carvalho^a, J. Fidalgo^a, K.R. Melo^b, M.F. Queiroz^b, S. Leal^a, H.A. Rocha^b, T. Cruz^{c,d}, P. Parpot^{a,e}, A.M. Tomás^{c,d,f}, M. Gama^{a,*}

^a CEB - Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal

^b Departamento de Bioquímica, Centro de Biociências, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil

^c i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal

^d IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal

^e Centre of Chemistry, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal

^f ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal

The authors regret to inform that there are some inaccuracies in the above referred article. More specifically, in the end of the Results and Discussion section 3.6. Anti-Leishmania activity against axenic promastigote and intramacrophagic *L. infantum* amastigotes it is described the following “Dex-AmB nanocomplexes had an activity similar to the free-drug, despite the slightly higher IC₅₀ values - 0.017 ± 0.009 and 0.023 ± 0.006 μM for Dex-AmB FD and Dex-AmB SD, respectively - promoting a decrease in the amastigote parasite burden in the used concentration range. These results are consistent with the literature where reduced and unreduced AmB-AG conjugates were able to decrease the percentage of macrophages infected with *L. infantum* (ED₅₀ of

0.035 mg/mL and 0.027 mg/mL, respectively) [75]”. In this sentence the units “mg/mL” are incorrect and the correct ones are “μg/mL”. Moreover, the reference numbered with 75 should be “J. Golenser, et al., Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob Agents Chemother 43(9) (1999) 2209-14” instead of “R. Falk, et al. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob. Agents Chemother., 43 (8) (1999), pp. 1975-1981”.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.ijbiomac.2020.03.019>.

* Corresponding author at: Department of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.

E-mail address: fmgama@deb.uminho.pt (M. Gama).

<https://doi.org/10.1016/j.ijbiomac.2020.07.193>

0141-8130/© 2020 Elsevier B.V. All rights reserved.